Related references
Note: Only part of the references are listed.VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
Long Yuan et al.
TRENDS IN IMMUNOLOGY (2021)
PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity
Sijia He et al.
VIRUSES-BASEL (2021)
Bi-directional differentiation of single bronchioalveolar stem cells during lung repair
Kuo Liu et al.
CELL DISCOVERY (2020)
PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells
Yajing Fu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature
Alessandro Mangogna et al.
DIAGNOSTICS (2020)
New emerging targets in cancer immunotherapy: the role of VISTA
Marco Tagliamento et al.
ESMO Open (2020)
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
Ji-Yoon Noh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
VISTA is an acidic pH-selective ligand for PSGL-1
Robert J. Johnston et al.
NATURE (2019)
Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma
Xiaoli Wang et al.
HEMATOLOGY (2019)
The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)
Ivonne A. Montes-Mojarro et al.
CANCERS (2018)
Targeting the PSGL-1 pathway for immune modulation
Roberto Tinoco et al.
IMMUNOTHERAPY (2017)
PSGL-1: A New Player in the Immune Checkpoint Landscape
Roberto Tinoco et al.
TRENDS IN IMMUNOLOGY (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion (vol 44, pg 1190, 2016)
Roberto Tinoco et al.
IMMUNITY (2016)
Basics of PD-1 in self-tolerance, infection, and cancer immunity
Shunsuke Chikuma
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
Antibody-drug conjugates for cancer therapy
Anish Thomas et al.
LANCET ONCOLOGY (2016)
Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib
Barbara Muz et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma
Andre Weilemann et al.
BLOOD (2015)
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice
P. Macor et al.
LEUKEMIA (2015)
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
Edgardo R. Parrilla Castellar et al.
BLOOD (2014)
CD30: from basic research to cancer therapy
Hiromi Muta et al.
IMMUNOLOGIC RESEARCH (2013)
Regulatory T Cells Suppress the Late Phase of the Immune Response in Lymph Nodes through P-Selectin Glycoprotein Ligand-1
Stefano Angiari et al.
JOURNAL OF IMMUNOLOGY (2013)
Lipid Raft Is Required for PSGL-1 Ligation Induced HL-60 Cell Adhesion on ICAM-1
Tingshuang Xu et al.
PLOS ONE (2013)
Ezrin-Radixin-Moesin-binding Sequence of PSGL-1 Glycoprotein Regulates Leukocyte Rolling on Selectins and Activation of Extracellular Signal-regulated Kinases
Caroline Spertini et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) γ2 and PI3Kγ pathways
Helena Mueller et al.
BLOOD (2010)
Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations
Eva Geissinger et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function
David Warde-Farley et al.
NUCLEIC ACIDS RESEARCH (2010)
P-Selectin Glycoprotein Ligand-1 as a Potential Target for Humoral Immunotherapy of Multiple Myeloma
C. Tripodo et al.
CURRENT CANCER DRUG TARGETS (2009)
PSGL-1 function in immunity and steady state homeostasis
Douglas A. Carlow et al.
IMMUNOLOGICAL REVIEWS (2009)
The structure, regulation, and function of ZAP-70
Byron B. Au-Yeung et al.
IMMUNOLOGICAL REVIEWS (2009)
PSGL-1-dependent myeloid leukocyte activation
Alexander Zarbock et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
A Role for E2F Activities in Determining the Fate of Myc-Induced Lymphomagenesis
Rachel E. Rempel et al.
PLOS GENETICS (2009)
Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified
Yuji Hirata et al.
LEUKEMIA RESEARCH (2008)
Functional role of p-selectin glycoprotein ligand 1/P-Selectin interaction in the generation of tolerogenic dendritic cells
Ana Urzainqui et al.
JOURNAL OF IMMUNOLOGY (2007)
Evolutionary conservation of P-selectin glycoprotein ligand-1 primary structure and function
Benedicte Baisse et al.
BMC EVOLUTIONARY BIOLOGY (2007)
Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets
Pier Paolo Piccaluga et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Lipid raft adhesion receptors and Syk regulate selectin-dependent rolling under flow conditions
Claire Abbal et al.
BLOOD (2006)
Identification of CD162 in plasma-cell dyscrasia
AM Florena et al.
LANCET ONCOLOGY (2005)
Cross-linking of P-selectin glycoprotein ligand-1 induces death of activated T cells
SC Chen et al.
BLOOD (2004)
Share Paper
